{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:20:36Z","timestamp":1777026036740,"version":"3.51.4"},"reference-count":33,"publisher":"Aboutscience Srl","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Circ Biomark"],"abstract":"<jats:p>Background: Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease, and it significantlyincreases the risk of cardiovascular disease and death. The evaluation of cardiovascular risk (CVR) is crucial inthese patients, but it may be underestimated using the current criteria, as they do not include nontraditionalCVR factors. Soluble ST-2, which is the circulating form of the IL-33 receptor, has been identified as a biomarkerfor cardiovascular and rheumatic diseases. In this study, we examined the role of sST-2 in assessing CVR in RA.Methods: Monocentric, retrospective, observational trial. Inclusion of RA patients on variable DMARD therapy.Analysis of RA disease using established scores (DAS 28, VAS, HFQ), clinical findings (number of swollen and painfuljoints), and laboratory investigation. Documentation of numerous CVR variables. Quantification of solublesST-2 by ELISA.Results: In total, 129 individuals were included. Soluble sST-2 did neither correlate nor was associated with anyvariable of RA disease activity. In contrast, significant associations were identified between sST-2 and a numberof established CVR markers.Conclusions: The data indicates a novel role for sST-2 in CVR prediction in RA.<\/jats:p>","DOI":"10.33393\/jcb.2025.3175","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:02:26Z","timestamp":1753707746000},"page":"5-11","source":"Crossref","is-referenced-by-count":1,"title":["Soluble interleukin-33 receptor (sST-2): a novel marker for assessing cardiovascular risk in rheumatoid arthritis"],"prefix":"10.33393","volume":"14","author":[{"given":"Inga","family":"Claus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meike","family":"Hoffmeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantin","family":"Remus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Dammermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ourania","family":"Gioti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6914-5254","authenticated-orcid":false,"given":"Daniel","family":"Patschan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susann","family":"Patschan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18642","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"17067","doi-asserted-by":"crossref","unstructured":"Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum. 2010;62(6):1576-1582. https:\/\/doi.org\/10.1002\/art.27425 PMID:20191579","DOI":"10.1002\/art.27425"},{"key":"17068","doi-asserted-by":"crossref","unstructured":"Hunter TM, Boytsov NN, Zhang X, et al. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatol Int. 2017;37(9):1551-1557. https:\/\/doi.org\/10.1007\/s00296-017-3726-1 PMID:28455559","DOI":"10.1007\/s00296-017-3726-1"},{"key":"17069","doi-asserted-by":"crossref","unstructured":"Fragoulis GE, Panayotidis I, Nikiphorou E. Cardiovascular risk in rheumatoid arthritis and mechanistic links: from pathophysiology to treatment. Curr Vasc Pharmacol. 2020;18(5):431-446. https:\/\/doi.org\/10.2174\/1570161117666190619143842 PMID:31258091","DOI":"10.2174\/1570161117666190619143842"},{"key":"17070","doi-asserted-by":"crossref","unstructured":"Meng H, Cheng IT, Yan BPY, et al. Moderate and high disease activity levels increase the risk of subclinical atherosclerosis progression in early rheumatoid arthritis: a 5-year prospective study. RMD Open. 10. Januar 2024;10(1):e003488. DOI: 10.1136\/rmdopen-2023-003488","DOI":"10.1136\/rmdopen-2023-003488"},{"key":"17071","doi-asserted-by":"crossref","unstructured":"Choy E, Ganeshalingam K, Semb AG, et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford). 2014;53(12):2143-2154. https:\/\/doi.org\/10.1093\/rheumatology\/keu224 PMID:24907149","DOI":"10.1093\/rheumatology\/keu224"},{"key":"17072","doi-asserted-by":"crossref","unstructured":"Atchison JW, Herndon CM, Rusie E. NSAIDs for musculoskeletal pain management:current perspectives and novel strategies to improve safety. J Manag Care Pharm. 2013;19(9)(suppl A):S3-S19. PMID:24261788","DOI":"10.18553\/jmcp.2013.19.s9.1"},{"key":"17073","doi-asserted-by":"crossref","unstructured":"Atzeni F, Rodr\u00edguez-Carrio J, Popa CD, et al. Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(5):270-290. https:\/\/doi.org\/10.1038\/s41584-021-00593-3 PMID:33833437","DOI":"10.1038\/s41584-021-00593-3"},{"key":"17074","doi-asserted-by":"crossref","unstructured":"Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis. 2017;76(1):17-28. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209775 PMID:27697765","DOI":"10.1136\/annrheumdis-2016-209775"},{"key":"17075","doi-asserted-by":"crossref","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104. DOI: 10.1093\/eurheartj\/ehy339","DOI":"10.1093\/eurheartj\/ehy439"},{"key":"17076","doi-asserted-by":"crossref","unstructured":"Popescu D, Rezus E, Badescu MC, et al. Cardiovascular risk assessment in rheumatoid arthritis: accelerated atherosclerosis, new biomarkers, and the effects of biological therapy. Life Basel Switz. 2023;13(2):319. DOI: 10.3390\/life13020319","DOI":"10.3390\/life13020319"},{"key":"17077","doi-asserted-by":"crossref","unstructured":"Curtis JR, Xie F, Crowson CS, et al. Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients. Arthritis Res Ther. 4. 2020;22(1):282. DOI: 10.1186\/s13075-020-02355-0","DOI":"10.1186\/s13075-020-02355-0"},{"key":"17078","doi-asserted-by":"crossref","unstructured":"Al-Maini M, Maindarkar M, Kitas GD, et al. Artificial intelligence-based preventive, personalized and precision medicine for cardiovascular disease\/stroke risk assessment in rheumatoid arthritis patients: a narrative review. Rheumatol Int. 2023;43(11):1965-1982. https:\/\/doi.org\/10.1007\/s00296-023-05415-1 PMID:37648884","DOI":"10.1007\/s00296-023-05415-1"},{"key":"17079","doi-asserted-by":"crossref","unstructured":"Fields JK, G\u00fcnther S, Sundberg EJ. Structural basis of IL-1 family cytokine signaling. Front Immunol. 2019;10:1412. https:\/\/doi.org\/10.3389\/fimmu.2019.01412 PMID:31281320","DOI":"10.3389\/fimmu.2019.01412"},{"key":"17080","doi-asserted-by":"crossref","unstructured":"Ouyang T, Song L, Fang H, et al. Potential mechanistic roles of Interleukin-33 in rheumatoid arthritis. Int Immunopharmacol. 2023;123:110770. https:\/\/doi.org\/10.1016\/j.intimp.2023.110770 PMID:37562293","DOI":"10.1016\/j.intimp.2023.110770"},{"key":"17081","doi-asserted-by":"crossref","unstructured":"Bao YS, Na SP, Zhang P, et al. Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease. J Clin Immunol. 2012;32(3):587-594. https:\/\/doi.org\/10.1007\/s10875-011-9622-7 PMID:22203232","DOI":"10.1007\/s10875-011-9622-7"},{"key":"17082","doi-asserted-by":"crossref","unstructured":"Shakerian L, Kolahdooz H, Garousi M, et al. IL-33\/ST2 axis in autoimmune disease. Cytokine. 2022;158:156015. https:\/\/doi.org\/10.1016\/j.cyto.2022.156015 PMID:36041312","DOI":"10.1016\/j.cyto.2022.156015"},{"key":"17083","doi-asserted-by":"crossref","unstructured":"Hong YS, Moon SJ, Joo YB, et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci. 2011;26(9):1132-1139. https:\/\/doi.org\/10.3346\/jkms.2011.26.9.1132 PMID:21935266","DOI":"10.3346\/jkms.2011.26.9.1132"},{"key":"17084","doi-asserted-by":"crossref","unstructured":"Dudek M, Ka\u0142u\u017cna-Oleksy M, Migaj J, et al. Clinical value of soluble ST2 in cardiology. Adv Clin Exp Med. 2020;29(10):1205-1210. https:\/\/doi.org\/10.17219\/acem\/126049 PMID:33049127","DOI":"10.17219\/acem\/126049"},{"key":"17085","doi-asserted-by":"crossref","unstructured":"Zagidullin N, Motloch LJ, Gareeva D, et al. Combining novel biomarkers for risk stratification of two-year cardiovascular mortality in patients with ST-elevation myocardial infarction. J Clin Med. 18. 2020;9(2):550. DOI: 10.3390\/jcm9020550","DOI":"10.3390\/jcm9020550"},{"key":"17086","doi-asserted-by":"crossref","unstructured":"Bayes-Genis A, Richards AM, Maisel AS, et al. Multimarker testing with ST2 in chronic heart failure. Am J Cardiol. 2015;115(7)(suppl):76B-80B. https:\/\/doi.org\/10.1016\/j.amjcard.2015.01.045 PMID:25697916","DOI":"10.1016\/j.amjcard.2015.01.045"},{"key":"17087","doi-asserted-by":"crossref","unstructured":"Erfurt S, Hoffmeister M, Oess S, et al. Soluble IL-33 receptor predicts survival in acute kidney injury. J Circ Biomark. 2022;11:28-35. https:\/\/doi.org\/10.33393\/jcb.2022.2386 PMID:35707675","DOI":"10.33393\/jcb.2022.2386"},{"key":"17088","doi-asserted-by":"crossref","unstructured":"Kay J, Upchurch KS. ACR\/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012;51(suppl 6):vi5-vi9. https:\/\/doi.org\/10.1093\/rheumatology\/kes279 PMID:23221588","DOI":"10.1093\/rheumatology\/kes279"},{"key":"17089","doi-asserted-by":"crossref","unstructured":"Lautenschl\u00e4ger J, Mau W, Kohlmann T, et al. [Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire]. Z Rheumatol. 1997;56(3):144-155. PMID:9340955","DOI":"10.1007\/s003930050030"},{"key":"17090","doi-asserted-by":"crossref","unstructured":"Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482-487. https:\/\/doi.org\/10.1136\/ard.2010.135871 PMID:21216812","DOI":"10.1136\/ard.2010.135871"},{"key":"17091","doi-asserted-by":"crossref","unstructured":"Toms TE, Panoulas VF, Douglas KMJ, et al. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis? Angiology. 2011;62(2):167-175. https:\/\/doi.org\/10.1177\/0003319710373749 PMID:20682616","DOI":"10.1177\/0003319710373749"},{"key":"17092","doi-asserted-by":"crossref","unstructured":"Liao KP, Cai T, Gainer VS, et al. Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population. Arthritis Care Res (Hoboken). 2013;65(12):2046-2050. https:\/\/doi.org\/10.1002\/acr.22091 PMID:23925980","DOI":"10.1002\/acr.22091"},{"key":"17093","doi-asserted-by":"crossref","unstructured":"England BR, Thiele GM, Anderson DR, et al. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 23. 2018;361:k1036. https:\/\/doi.org\/10.1136\/bmj.k1036","DOI":"10.1136\/bmj.k1036"},{"key":"17094","doi-asserted-by":"crossref","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 7. 2021;42(34):3227\u2013337. DOI: 10.1093\/eurheartj\/ehab484","DOI":"10.1093\/eurheartj\/ehab484"},{"key":"17095","doi-asserted-by":"crossref","unstructured":"Kellner H, Bornholdt K, Hein G. Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study. Clin Rheumatol. 2010;29(8):913-920. https:\/\/doi.org\/10.1007\/s10067-010-1425-3 PMID:20496042","DOI":"10.1007\/s10067-010-1425-3"},{"key":"17096","doi-asserted-by":"crossref","unstructured":"Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480-489. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206624 PMID:25561362","DOI":"10.1136\/annrheumdis-2014-206624"},{"key":"17097","doi-asserted-by":"crossref","unstructured":"Bodur H. Cardiovascular comorbidities in spondyloarthritis. Clin Rheumatol. 2023;42(10):2611-2620. https:\/\/doi.org\/10.1007\/s10067-022-06473-9 PMID:36512164","DOI":"10.1007\/s10067-022-06473-9"},{"key":"17098","doi-asserted-by":"crossref","unstructured":"Han JH, Suh CH, Jung JY, et al. Serum levels of interleukin 33 and soluble ST2 are associated with the extent of disease activity and cutaneous manifestations in patients with active adult-onset Still\u2019s disease. J Rheumatol. 2017;44(6):740-747. https:\/\/doi.org\/10.3899\/jrheum.170020 PMID:28365573","DOI":"10.3899\/jrheum.170020"},{"key":"17099","doi-asserted-by":"crossref","unstructured":"Jung SM, Lee J, Baek SY, et al. The Interleukin 33\/ST2 axis in patients with primary Sj\u00f6gren syndrome: expression in serum and salivary glands, and the clinical association. J Rheumatol. 2015;42(2):264-271. https:\/\/doi.org\/10.3899\/jrheum.140234 PMID:25512474","DOI":"10.3899\/jrheum.140234"}],"container-title":["Journal of Circulating Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/download\/3175\/4060","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/download\/3175\/4061","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/download\/3175\/4060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:02:34Z","timestamp":1753707754000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/view\/3175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,6,9]]}},"URL":"https:\/\/doi.org\/10.33393\/jcb.2025.3175","relation":{},"ISSN":["1849-4544","1849-4544"],"issn-type":[{"value":"1849-4544","type":"electronic"},{"value":"1849-4544","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}